Frontlight ResearchEarly access
Not yet taking people in SwedenPhase 2
Tests tadalafil to help sexual function after rectal cancer treatment
Tests tadalafil in men and women after treatment for rectal cancer.
Key facts
- Who runs it
- Karolinska Institutet
- Where
- Gothenburg, Malmo, and Solna, SwedenSee the 3 sites
- Registry title
- Early intervention and recovery of sexual function in men and women after treatment of rectal cancer–a randomized placebo-controlled study with tadalafil
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 80 people, planned
- Started
- 7 Dec 2020
- Planned end
- 30 Jun 2026
- Type of study
- Interventional
- Record updated
- 27 September 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men and women with stage I-III rectal cancer who plan to have abdominal surgery to remove it and were sexually active before the diagnosis.
- Age
- Over 18 years
- Sex
- Men and women
- Disease stage
- Rectal cancer stage I-III, with surgery by the abdominal route planned.
- Earlier treatment
- Must not have had pelvic radiation. Must not be using anti-androgens or androgens.
Main reasons for not taking part
- Cancer that has spread (metastases)
- History of cancer of the urinary or genital organs
- Reasons why tadalafil (a PDE5-inhibitor) cannot be used
- ECOG performance score above 1
- Serious mental disorder or medical condition, such as anaemia, liver or kidney failure, heart disease or diabetes
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Men and women with rectal cancer stage I-III after clinical and radiologic staging, intention to transabdominal resection of rectal cancer
- Patient reported sexual activity before diagnosis or symptoms of rectal cancer according to FSFI-6 and IIEF-5
- Age over 18 years
- Fluent in oral and written Swedish language
- Females must not be lactating or pregnant at baseline documented by pregnancy test
- Given written informed consent
Who cannot take part
- Concomitant use of anti-androgens or androgens
- Contraindications to the use of tadalafil (PDE5-inhibitor)
- Ongoing drug or alcohol abuse dependence
- Has a condition or has received medical treatment that, in the judgement of the investigator, precluded successful participation in the study
- Evidence of systemic disease (metastases)
- History or evidence of urogenital malignancy
- History of pelvic radiation
- Serious co-existing mental disorder or medical condition e.g. anaemia, liver or renal failure, cardiovascular disease or diabetes
- Impaired performance status (Eastern Cooperative Oncology Group (ECOG) performance score above 1
Where in Sweden
- Sahlgrenska University Hospital-Vaestra GoetalandsregionenGothenburg, SwedenNot yet recruiting
- Region Skane Skanes UniversitetssjukhusMalmo, SwedenNot yet recruiting
- Karolinska University HospitalSolna, SwedenNot yet recruiting
About the trial
What the trial wants to find out
To evaluate the effect of prophylactic intake of 5 mg tadalafil on sexual/erectile function in women and men within a standardized rehabilitation program after treatment for rectal cancer.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Early intervention and recovery of sexual function in men and women after treatment of rectal cancer–a randomized controlled study with tadalafil compared to standard care
- Plain-language title
- Tests tadalafil to help sexual function after rectal cancer treatmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 27 September 2024